Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    July 2017

  1. Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2017;23:3973.
    PubMed     Text format    



  2. Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:3970.
    PubMed     Text format    


    June 2017
  3. BILUSIC M, Madan RA, Gulley JL
    Immunotherapy of Prostate Cancer: Facts and Hopes.
    Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
    PubMed     Text format     Abstract available


  4. XU L, Mao X, Guo T, Chan PY, et al
    The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
    Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
    PubMed     Text format     Abstract available


    May 2017
  5. BAN K, Feng S, Shao L, Ittmann M, et al
    RET signaling in prostate cancer.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
    PubMed     Text format     Abstract available


  6. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
    Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
    Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
    PubMed     Text format     Abstract available


    April 2017
  7. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
    Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
    PubMed     Text format     Abstract available


  8. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Text format     Abstract available


    March 2017
  9. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Text format     Abstract available


    February 2017
  10. RATHKOPF DE, Antonarakis ES, Shore ND, Tutrone RF, et al
    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
    Clin Cancer Res. 2017 Feb 17. pii: clincanres.2509.2016.
    PubMed     Text format     Abstract available


  11. SAXENA R, Yang C, Rao M, Turaga RC, et al
    Preclinical development of a non-toxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment.
    Clin Cancer Res. 2017 Feb 6. pii: clincanres.1716.2016.
    PubMed     Text format     Abstract available


    January 2017
  12. WANG R, Wang J, Gao G, Hu J, et al
    Pre-biopsy mp-MRI can help to improve the predictive performance in prostate cancer: a prospective study in 1478 consecutive patients.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2884.2016.
    PubMed     Text format     Abstract available


  13. KIM K, Zhang H, LaRosa S, Jebiwott S, et al
    Bombesin Antagonist Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2745.2016.
    PubMed     Text format     Abstract available


  14. CASTIELLO L, Sabatino M, Ren J, Terabe M, et al
    Expression of CD14, IL-10 and tolerogenic signature in dendritic cells inversely correlate with response to TARP vaccination in prostate cancer patients.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2199.2016.
    PubMed     Text format     Abstract available



  15. Correction: Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:323.
    PubMed     Text format    


    December 2016
  16. LAM HM, McMullin R, Nguyen H, Coleman I, et al
    Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2054.2016.
    PubMed     Text format     Abstract available


    November 2016
  17. ANTONARAKIS ES, Kibel AS, Yu EY, Karsh LI, et al
    Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial.
    Clin Cancer Res. 2016 Nov 10. pii: clincanres.1780.2016.
    PubMed     Text format     Abstract available


  18. YIN Y, Zhang Q, Zhang H, He Y, et al
    Molecular signature to risk-stratify prostate cancer of intermediate risk.
    Clin Cancer Res. 2016 Nov 1. pii: clincanres.2400.2016.
    PubMed     Text format     Abstract available


    October 2016
  19. PENET MF, Kakkad S, Pathak AP, Krishnamachary B, et al
    Structure and Function of a Prostate Cancer Dissemination Permissive Extracellular Matrix.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1516.2016.
    PubMed     Text format     Abstract available


  20. SAYYID R, Evans A, Hersey K, Maloni R, et al
    A Phase II, Randomized, Open Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Clin Cancer Res. 2016 Oct 18. pii: clincanres.1790.2016.
    PubMed     Text format     Abstract available


  21. PALAPATTU GS, Salami SS, Cani AK, Hovelson DH, et al
    Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.
    Clin Cancer Res. 2016 Oct 7. doi: 10.1158/1078-0432.CCR-16-1454.
    PubMed     Text format     Abstract available


  22. KUHN P, Carlsson A, Luttgen MS, Dizon KK, et al
    Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1355.2016.
    PubMed     Text format     Abstract available


    September 2016
  23. TAPLIN ME, McKay RR, Werner L, Mostaghel EA, et al
    A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0987.2016.
    PubMed     Text format     Abstract available


  24. BRAGELMANN J, Klumper N, Offermann A, von Massenhausen A, et al
    Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0094.2016.
    PubMed     Text format     Abstract available


  25. HELLER G, Fizazi K, McCormack RT, Molina A, et al
    The added value of circulating tumour cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1224.2016.
    PubMed     Text format     Abstract available


  26. LUK IS, Shrestha R, Xue H, Wang Y, et al
    BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0718.2016.
    PubMed     Text format     Abstract available


  27. GUPTA S, Li J, Kemeny G, Bitting RL, et al
    Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide resistant metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1211.2016.
    PubMed     Text format     Abstract available


    August 2016
  28. QU F, Xie W, Nakabayashi M, Zhang H, et al
    Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1070.2016.
    PubMed     Text format     Abstract available


  29. REBELLO RJ, Kusnadi E, Cameron DP, Pearson HB, et al
    The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer.
    Clin Cancer Res. 2016 Aug 2. pii: clincanres.0124.2016.
    PubMed     Text format     Abstract available


    July 2016
  30. SHOURIDEH M, Azabdaftari G, Attwood K, DePriest A, et al
    GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016.
    PubMed     Text format     Abstract available


  31. SAYLOR PJ, Lee RJ, Arora KS, Deshpande V, et al
    Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0237.2016.
    PubMed     Text format     Abstract available



  32. Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Clin Cancer Res. 2016;22:3702.
    PubMed     Text format    


    June 2016
  33. ZHAO S, Geybels MS, Leonardson A, Rubicz R, et al
    Epigenome-wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-lethal Progression in Men with Clinically Localized Prostate Cancer.
    Clin Cancer Res. 2016 Jun 29. pii: clincanres.0549.2016.
    PubMed     Text format     Abstract available


  34. SHARP A, Welti J, Blagg J, de Bono JS, et al
    Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.1137.2016.
    PubMed     Text format     Abstract available


  35. BANSAL N, Bartucci M, Yusuff S, Davis S, et al
    BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.3107.2015.
    PubMed     Text format     Abstract available


  36. YAMIN G, Schenker-Ahmed NM, Shabaik A, Adams D, et al
    Voxel Level Radiologic-Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer.
    Clin Cancer Res. 2016;22:2668-74.
    PubMed     Text format     Abstract available


    May 2016
  37. GUEDES L, Morais C, Almutairi F, Haffner MC, et al
    Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.
    Clin Cancer Res. 2016 May 10. pii: clincanres.0205.2016.
    PubMed     Text format     Abstract available


  38. YANG YC, Banuelos CA, Mawji NR, Wang J, et al
    Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer.
    Clin Cancer Res. 2016 May 2. pii: clincanres.2901.2015.
    PubMed     Text format     Abstract available


    April 2016
  39. CHEN X, Li Q, Liu X, Liu C, et al
    Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer (CRPC).
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.2956.2015.
    PubMed     Text format     Abstract available


    March 2016
  40. LOPEZ SM, Agoulnik AI, Zhang M, Peterson LE, et al
    Nuclear Receptor Corepressor 1 expression and output declines with prostate cancer progression.
    Clin Cancer Res. 2016 Mar 11. pii: clincanres.1983.2015.
    PubMed     Text format     Abstract available


  41. GAO S, Ye H, Gerrin S, Wang H, et al
    ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.2309.2015.
    PubMed     Text format     Abstract available


    February 2016
  42. MORRIS MJ, Rathkopf DE, Novotny W, Gibbons JA, et al
    Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 8. pii: clincanres.2638.2015.
    PubMed     Text format     Abstract available


  43. HUSSAIN M, Le Moulec S, Gimmi C, Bruns R, et al
    Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-resistant Prostate Cancer.
    Clin Cancer Res. 2016 Feb 2. pii: clincanres.2512.2015.
    PubMed     Text format     Abstract available


  44. HEDAYATI M, Haffner MC, Coulter J, Raval RR, et al
    Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation.
    Clin Cancer Res. 2016 Feb 1. pii: clincanres.1147.2015.
    PubMed     Text format     Abstract available


    January 2016
  45. LENNARTZ M, Minner S, Brasch S, Wittmann H, et al
    The combination of DNA ploidy status and PTEN/6q15 deletions provides strong and independent prognostic information in prostate cancer.
    Clin Cancer Res. 2016 Jan 26. pii: clincanres.0635.2015.
    PubMed     Text format     Abstract available


  46. CHOI SY, Xue H, Wu R, Fazli L, et al
    The MCT4 Gene: a Novel, Potential Target for Therapy of Advanced Prostate Cancer.
    Clin Cancer Res. 2016 Jan 11. pii: clincanres.1624.2015.
    PubMed     Text format     Abstract available



  47. Retraction: Suppression of N-Methyl-N-nitrosourea/Testosterone-Induced Rat Prostate Cancer Growth by Celecoxib: Effects on Cyclooxygenase-2, Cell Cycle Regulation, and Apoptosis Mechanism(s).
    Clin Cancer Res. 2016;22:270.
    PubMed     Text format    


  48. HABERKORN U, Eder M, Kopka K, Babich JW, et al
    New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
    Clin Cancer Res. 2016;22:9-15.
    PubMed     Text format     Abstract available


    December 2015
  49. ZHANG W, Yi B, Wang C, Chen D, et al
    Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.1927.2015.
    PubMed     Text format     Abstract available


  50. VAN LEEUWEN FW, van der Poel HG
    Surgical Guidance in Prostate Cancer: "From Molecule to Man" Translations.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2575.2015.
    PubMed     Text format     Abstract available


  51. KATO M, Banuelos CA, Imamura Y, Leung JK, et al
    Co-targeting Androgen Receptor Splice Variants and mTOR signaling pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2119.2015.
    PubMed     Text format     Abstract available


  52. BELTRAN H, Jendrisak A, Landers M, Mosquera JM, et al
    The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2015 Dec 15. pii: clincanres.0137.2015.
    PubMed     Text format     Abstract available


  53. ZHAO SG, Evans JR, Kothari V, Sun G, et al
    The landscape of prognostic outlier genes in high-risk prostate cancer.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.1250.2015.
    PubMed     Text format     Abstract available


    November 2015
  54. GEVENSLEBEN H, Dietrich D, Golletz C, Steiner S, et al
    The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer.
    Clin Cancer Res. 2015 Nov 16. pii: clincanres.2042.2015.
    PubMed     Text format     Abstract available


  55. MEHRA N, Zafeiriou Z, Lorente D, Terstappen LW, et al
    CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.
    Clin Cancer Res. 2015;21:4992-5.
    PubMed     Text format     Abstract available


    March 2015
  56. SHARIFI N
    Steroid sidestep: evading androgen ablation by abiraterone.
    Clin Cancer Res. 2015;21:1240-2.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: